Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial ; day:25 ; month:5 ; year:2023 ; pages:1-3
Cardiovascular drugs and therapy ; (25.5.2023), 1-3
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10557-023-07470-z
- URN
-
urn:nbn:de:101:1-2023091013110224475926
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hammer, Andreas
- Niessner, Alexander
- Sulzgruber, Patrick
- SpringerLink (Online service)
Ähnliche Objekte (12)
Initial rivaroxaban dosing in patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Cryoablation in persistent atrial fibrillation – a critical appraisal
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Initial rivaroxaban dosing in patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Cryoablation in persistent atrial fibrillation – a critical appraisal
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Initial rivaroxaban dosing in patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Cryoablation in persistent atrial fibrillation – a critical appraisal
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation